)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
GeoVax Labs (GOVX) investor relations material
GeoVax Labs Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Advanced development of GEO-MVA (mpox/smallpox vaccine), GEO-CM04S1 (multi-antigen COVID-19 vaccine), and Gedeptin (oncology therapy), with expedited EMA guidance allowing GEO-MVA to proceed directly to phase III trials and new needle-free delivery collaborations.
Strong Phase 2 data for GEO-CM04S1 in immunocompromised patients, with superior immune responses to mRNA vaccines and increased industry and government interest.
Gedeptin® expanded into new solid tumor indications, with Phase 2 trial in head and neck cancer and preclinical studies in other cancers.
Ongoing collaborations, manufacturing scale-up, and alignment with U.S. pandemic preparedness and global health equity priorities.
Priorities for 2025–2026 include advancing clinical programs, expanding manufacturing, and pursuing strategic partnerships.
Financial highlights
Revenue for the nine months ended September 30, 2025, was $2.5M, down from $3.1M in 2024, primarily due to the termination of the BARDA Project NextGen contract.
Q3 2025 net loss was $6.3M ($0.31/share), with a nine-month net loss of $17.0M ($0.97/share), both slightly higher than 2024.
R&D expenses for Q3 2025 were $5.0M (down from $7.4M in 2024); nine-month R&D expense was $15.1M (down from $16.1M in 2024).
General and administrative expenses for Q3 2025 were $1.3M; nine-month G&A expense was $4.6M (up from $3.8M in 2024).
Cash balance at September 30, 2025, was $5.0M, down from $5.5M at December 31, 2024, reflecting $16.5M used in operations and $16M raised via financing.
Outlook and guidance
EMA and BARDA-aligned regulatory strategy positions GEO-MVA for accelerated commercialization, with clinical material expected for evaluation early next year and a phase III trial planned.
Next-generation COVID-19 vaccine construct targeting Omicron KP.2 planned for 2026 trial launch.
Phase 2 trial of Gedeptin® in head and neck cancer scheduled for initiation in 2H 2026.
Anticipated business partnerships and collaborations to support global development and commercialization.
Focused on extending cash runway through strategic partnerships, non-dilutive funding, or additional equity offerings; substantial doubt remains about ability to continue as a going concern without new capital.
GEO-MVA: How does EMA guidance impact market entry?
Gedeptin: Rationale for first-line therapy trial design?
What is the cash runway extension strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next GeoVax Labs earnings date
Q4 202525 Mar, 2026
Next GeoVax Labs earnings date
Q4 202525 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
GeoVax Labs Inc is a biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancer. The company utilizes its proprietary vaccine platforms to target viral and bacterial pathogens, as well as tumor-associated antigens. Its development pipeline includes both preventive and therapeutic candidates undergoing preclinical and clinical testing. GeoVax Labs Inc is headquartered in Smyrna, Georgia, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage